CANCER EPIDEMIOLOGY PROGRAM The Cancer Epidemiology program studies environmental, genetic, and molecular risks for cancer and cancer outcomes to identify priorities for public health and clinical intervention. The program has three aims: (1) Risk- Based Prevention and Early Detection: To identify opportunities for risk-based prevention and early detection of cancer; (2) Treatment, Outcomes and Survivorship: To improve cancer treatment, outcomes, and survivorship through epidemiologic and clinical research that leads to evidence-based interventions; (3) Integrative Molecular Epidemiology: To deepen understanding of cancer etiology, heterogeneity, and survivorship through integrative human molecular and histopathologic studies of precursor lesions and tumors. A major cross-cutting theme is addressing the epidemiology of health disparities. As a comprehensive cancer center in an economically, socially, and racially diverse state, CE is well-poised to address health equity. Across these aims, we use multidimensional North Carolina studies and conduct cross-program research to yield high impact findings. Members have expertise in population-based epidemiology, data linkage, pharmacoepidemiology, survey research, clinical research, screening, molecular and biomarker research, translational preclinical research, sociology, pathology, genomics, data science, computer science, and statistical and epidemiologic methods. Research resources include population-based studies of breast, colon, prostate, head and neck cancer as well as registries for breast and lung screening. Many of these studies participate in large national and international data-sharing initiatives and consortia. The Program brings value to the Center through study resources that collect exposure and outcome data, and biospecimens, a unique shared resource (Statewide Cancer Data), and expertise in epidemiologic methods. The Program is supported by UNC Lineberger?s investments in faculty recruitments, shared resources and developmental funds. The UNC Lineberger strategic plan emphasis on optimizing cancer outcomes in North Carolina has led to significant investment across population sciences and is expanding in new areas in coming years including endometrium and bladder, with sustained support for ongoing data collection in breast cancer and head and neck cancers. The CE Program consists of 33 members who are associated with 9 departments at UNC- Chapel Hill and affiliated institutions. During the last funding period, program members have published 776 cancer-related articles, 24% were inter-programmatic and 19% were intra-programmatic (34% collaborative). In 2019, our program members held grants totaling $10.0M (direct cost) in cancer-relevant extramural funding, including $5.2M (direct costs) from the NCI and $3.0M other peer-reviewed funding.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
2P30CA016086-45
Application #
10089819
Study Section
Subcommittee I - Transistion to Independence (NCI)
Project Start
1997-06-01
Project End
2025-11-30
Budget Start
2020-12-01
Budget End
2021-11-30
Support Year
45
Fiscal Year
2021
Total Cost
Indirect Cost
Name
University of North Carolina Chapel Hill
Department
Type
DUNS #
608195277
City
Chapel Hill
State
NC
Country
United States
Zip Code
27599
Hosseinipour, Mina C; Kang, Minhee; Krown, Susan E et al. (2018) As-Needed Vs Immediate Etoposide Chemotherapy in Combination With Antiretroviral Therapy for Mild-to-Moderate AIDS-Associated Kaposi Sarcoma in Resource-Limited Settings: A5264/AMC-067 Randomized Clinical Trial. Clin Infect Dis 67:251-260
Ren, Jianke; Hathaway, Nathaniel A; Crabtree, Gerald R et al. (2018) Tethering of Lsh at the Oct4 locus promotes gene repression associated with epigenetic changes. Epigenetics 13:173-181
Huang, Weigang; Wang, Xiaoyang; Endo-Streeter, Stuart et al. (2018) A membrane-associated, fluorogenic reporter for mammalian phospholipase C isozymes. J Biol Chem 293:1728-1735
Smitherman, Andrew B; Anderson, Chelsea; Lund, Jennifer L et al. (2018) Frailty and Comorbidities Among Survivors of Adolescent and Young Adult Cancer: A Cross-Sectional Examination of a Hospital-Based Survivorship Cohort. J Adolesc Young Adult Oncol 7:374-383
Zheng, Xiaojing; O'Connell, Catherine M; Zhong, Wujuan et al. (2018) Discovery of Blood Transcriptional Endotypes in Women with Pelvic Inflammatory Disease. J Immunol 200:2941-2956
Jenkins, Mark A; Win, Aung Ko; Templeton, Allyson S et al. (2018) Cohort Profile: The Colon Cancer Family Registry Cohort (CCFRC). Int J Epidemiol 47:387-388i
Williams, Rebecca S; Derrick, Jason; Liebman, Aliza K et al. (2018) Content analysis of e-cigarette products, promotions, prices and claims on Internet tobacco vendor websites, 2013-2014. Tob Control 27:e34-e40
McRee, Autumn J; Marcom, Paul K; Moore, Dominic T et al. (2018) A Phase I Trial of the PI3K Inhibitor Buparlisib Combined With Capecitabine in Patients With Metastatic Breast Cancer. Clin Breast Cancer 18:289-297
Efird, William M; Fletcher, Alex G; Draeger, Reid W et al. (2018) Deferoxamine-Soaked Suture Improves Angiogenesis and Repair Potential After Acute Injury of the Chicken Achilles Tendon. Orthop J Sports Med 6:2325967118802792
Patel, Nirali M; Michelini, Vanessa V; Snell, Jeff M et al. (2018) Enhancing Next-Generation Sequencing-Guided Cancer Care Through Cognitive Computing. Oncologist 23:179-185

Showing the most recent 10 out of 1525 publications